154775-43-6

Basic information

• Product Name: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID
• Synonyms: Boc-piperidine-4-propanoic acid;3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid;3-(1-tert-Butoxycarbonyl-4-piperidyl)propanoic acid;1-Boc-4-piperidinepropanoic acid;4-Piperidinepropanoic acid, 1-[(1,1-dimethylethoxy)carbonyl]-;N-Boc-piperidin-4-ylpropionic acid;N-BOC-PIPERIDINYL-4-PROPIONIC ACID;1-BOC-PIPERIDINE-4-PROPANOIC ACID
• CAS NO: 154775-43-6
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.33
• Product Categories: pharmacetical
• Mol File: 154775-43-6.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 386.4 °C at 760 mmHg
• Flash Point: 187.5 °C
• Appearance: /
• Density: 1.102 g/cm³
• Vapor Pressure: 4.83E-07mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 4.73±0.10(Predicted)
• CAS DataBase Reference: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID(154775-43-6)
• EPA Substance Registry System: 1-BOC-PIPERIDIN-4-YLPROPIONIC ACID(154775-43-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 154775-43-6(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C13H23NO4/c1-13(2,3)18-12(17)14-8-6-10(7-9-14)4-5-11(15)16/h10H,4-9H2,1-3H3,(H,15,16)/p-1

Upstream product

• 84228-93-3 3-(pyridin-4-yl)acrylic acid 
• 301232-45-1 tert-butyl 4-(3-ethoxy-3-oxopropyl)-1-piperidinecarboxylate 
• 162504-75-8 tert-butyl 4-(3-methoxy-3-oxopropyl)piperidine-1-carboxylate 
• 1822-32-8 3-(4-piperidyl)propionic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 5337-79-1 3-(4-pyridinyl)-2-propenoic acid 
• 301185-77-3 3-(1-(t-butoxycarbonyl)-4-piperidylidene)propionic acid 
• 166815-97-0 1-(tert-butoxycarbonyl)-4-[2,2-di(ethoxycarbonyl)ethyl]piperidine 
• 51052-79-0 3-(4-piperidinyl)propionic acid hydrochloride 
• 194933-85-2 4-((E)-2-Methoxycarbonyl-vinyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 

Downstream Products

• 721455-06-7 tert-butyl 4-{3-[(4R)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}piperidine-1-carboxylate 
• 1822-32-8 3-(4-piperidyl)propionic acid 
• 195877-48-6 4-[3-(4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxo-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 181073-79-0 C₁₃H₂₁NO₄ 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1085837-44-0 2,2-dimethyl-3-{5'-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl}-propionic acid 

Relevant articles and documents

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR, wherein R is O-, -CH3 or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR or CR; or each of a, b, c and d is independently selected from CR or CR; each R and each R is independently selected from H, halo, -CR3, -OR, -COR, -SR, -S(O)tR (wherein t is 0, 1 or 2), -SCN, -N(R)2, -NRR, -NO2, -OC(O)R, -CO2R, -OCO2R, -CN, -NHC(O)R, -NHSO2R, -CONHR, -CONHCH2CH2OH, -NRCOOR, -SRC(O)OR, -SRN(R); n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO2-; or -CRR-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR, -SR, -CRR, -NRR, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.

Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: Discovery of FK419

The discovery of the non-peptide antiplatelet injectable agent FK419 is reported. Based on the β-turn structure of RGD peptide sequences in the α chain of fibrinogen, which binds the glycoprotein IIb/IIIa (GPIIb/IIIa) on the surface of platelets to induce